INO-3107

INOVIO will showcase promising results of their DNA medicine INO-3107 at the AACR Immuno-Oncology Conference, demonstrating complete clearance of HPV-6 in Recurrent Respiratory Papillomatosis patients.

A phase Ib/II clinical trial led by Mount Sinai researchers demonstrates successful outcomes in combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma treatment.

INOVIO plans to submit a Biologics License Application (BLA) to the FDA for INO-3107 by mid-2025, seeking priority review for recurrent respiratory papillomatosis.

Inovio Pharmaceuticals, Inc., a biotechnology company focused on developing treatments for infectious diseases and cancer, is navigating through clinical advancements and operational challenges. Despite a promising product pipeline, including its lead program for recurrent respiratory papillomatosis (RRP), the company faces manufacturing setbacks that have delayed its regulatory timeline. Inovio's financial stability is under scrutiny as it burns through cash reserves, despite having a healthy current ratio. The company's future success hinges on resolving manufacturing issues, advancing its clinical trials, and navigating the competitive biotech landscape.

INOVIO's INO-3107 induced the expansion of new clonal T cells in the blood, previously undetectable, in patients with recurrent respiratory papillomatosis (RRP).